Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin for non-alcoholic fatty liver disease in adults with type 2 diabetes
IRCT20210811052150N1Phase 3Completed
- Sponsor
- Shahid Beheshti University of Medical Sciences
- Start
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of empagliflozin in metabolic dysfunction-associated steatotic liver disease (MASLD) (2 arms), sponsored by Shahid Beheshti University of Medical Sciences. Primary endpoints: Insulin and liver/metabolic laboratory measures at 6 months, Fatty liver severity by imaging at 6 months and 1 more. Started Aug 2021; status: completed.
02
Drugs
empagliflozin
03
Conditions
metabolic dysfunction-associated steatotic liver disease (MASLD)
Beyond the preview
Go deeper on IRCT20210811052150N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20210811052150N1.